Skip to main content

454 CEO Lands at Ensemble as CuraGen CEO Steps Down

NEW YORK, April 6 (GenomeWeb News) - CuraGen, the parent company of 454 Life Sciences, this week said that CEO Jonathan Rothberg will be stepping down.


In a separate announcement, Ensemble Discovery said it has hired former 454 president and CEO Richard Begley as its new president and CEO.


New Haven, Conn.-based CuraGen said it has begun to look for a new CEO, and that Rothberg will remain in his position until a replacement is appointed. Rothberg has been the chairman and CEO of the pharmaceutical company since it was founded seven years ago.


According to CuraGen, Patrick Zenner, a member of the board of directors, has been asked to chair the search committee for the new CEO, and Rothberg said in a statement that he would assist in the search.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.